KURA vs RVMD
KURA: Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships. RVMD: A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
Side-by-side fundamentals
| Metric | KURA | RVMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.54 | $183.03 | |
| Market cap as of 2026-07-23 | $944M | $39.0B | |
| PEG as of 2026-07-23 | -0.05 | -0.34 | RVMD lower |
| Net margin as of 2026-07-23 | -411.2% | -2833.9% | KURA higher |
| Gross margin as of 2026-07-23 | +99.9% | n/a | |
| Operating margin as of 2026-07-23 | -443.5% | -3145.0% | KURA higher |
| ROE as of 2026-07-23 | -141.9% | -54.1% | RVMD higher |
| ROA as of 2026-07-23 | -43.3% | -39.1% | RVMD higher |
| Debt / equity as of 2026-07-23 | 0.09 | 0.19 | KURA lower |
| Revenue growth (YoY) as of 2026-07-23 | +29.5% | n/a | |
| Beta as of 2026-07-23 | 0.37 | 1.41 | |
| 1-year return as of 2026-07-22 close | +58.0% | +378.3% | RVMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.